Saturday, October 3, 2026

USD/CNH Is 3% Down In The Last 21 Sessions

ViaNews Editorial Team

February 28, 2023

USD/CNH Is 3% Down In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 3.12% for the last 21 sessions. At 17:08 EST on Tuesday, 28 February, USD/CNH (USDCNH) is $6.95.

USD/CNH's yearly highs and lows, it's 0.127% up from its 52-week low and 0.185% down from its 52-week high.

News about

  • Usd/jpy price analysis: bears lurking near 136.50. According to FXStreet on Monday, 27 February, "In turn, USD/JPY rallied hard but it is now in a corrective territory as the following illustrates:"
  • According to FXStreet on Monday, 27 February, "The only thing preventing USD/JPY from continuing to retrace towards 140 is the dip in Treasury yields yesterday.''"
  • Usd/jpy: yen vulnerable to a further correction lower – MUFG. According to FXStreet on Monday, 27 February, "The recent move higher in US rates has helped to lift USD/JPY back above the 135.00level and it has continued to move closer to its' 200-Day Moving Average that comes in at around 137.10."
  • Usd/jpy remains on the defensive below YTD peak amid softer usd, bullish potential intact. According to FXStreet on Monday, 27 February, "Traders will further take cues from the broader risk sentiment to grab short-term opportunities around the USD/JPY pair.", "A softer tone surrounding the US Treasury bond yields trigger a modest US Dollar pullback from a seven-week high, which, in turn, is seen exerting some downward pressure on the USD/JPY pair. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com